Contract business boosts Progen revenue
12 September, 2002 by Pete YoungProgen Industries has posted a 58 per cent year-on-year revenue gain, due largely to the performance of its life sciences business, particularly its contract drug manufacturing unit.
Peplin rights issue bucks the trend
12 September, 2002 by Pete YoungListed company Peplin Biotech is proving that requests for fresh funds by young biotechs whose products are far from market-ready aren't receiving an automatic thumbs down from investors.
Axon posts loss as revenue slumps
12 September, 2002 by Pete YoungFormer share market favorite Axon Instruments has posted after-tax losses of $8.8 million on falling revenues for the half year to June 30.
Bio-septic system offers relief for the effluent society
11 September, 2002 by Graeme O'NeillOut of sight, out of mind, and far too often, out of order - that malodorous monster, the septic tank, lurks just below the ground in the back yards of more than 450,000 homes around Australia's eastern seaboard, from Queensland to Victoria. Another 200,000 households around New Zealand are unsewered.
Benitec hires management, gears up to commercialise
11 September, 2002 by Melissa TrudingerBrisbane biotech Benitec has added a managing director and a commercial director to its senior management team, as it prepares to expand its commercialisation activities.
New deal suggests FDA approval closer for Gradipore
11 September, 2002 by Iain ScottFDA approval for Sydney-based separation technology company Gradipore has come a step closer, after the signing of a new agreement with Canadian hyperimmune product specialist Cangene.
Norwood Abbey raises $4.13 million
10 September, 2002 by Melissa TrudingerNorwood Abbey has raised $4.13 million in a placement to institutional and professional investors.
Solbec hires Bioscience to grow anti-cancer ingredient
10 September, 2002 by Melissa TrudingerWestern Australian horticulture company Bioscience has been commissioned by Solbec Pharmaceuticals to set up and run Solbec's horticultural production facility, used to produce its lead anti-cancer compound from Solanum linnaeanum, or devil's apple.
Lucre for Bioglobal's LuciLure
10 September, 2002 by Melissa TrudingerBioglobal has signed an exclusive three-year agreement to market and distribute its LuciLure blowfly trap for sheep protection and landfill markets in Australia and New Zealand.
Novogen claims success in heart drug trial
10 September, 2002 by Graeme O'NeillSydney pharmaceutical company Novogen says the first human clinical trial of its candidate heart-disease therapeutic NV-04 has confirmed the "outstanding potency" it showed in initial trials in laboratory animals.
Meditech teams up to market skin cancer treatment
10 September, 2002 by Graeme O'NeillMeditech Research and SkyePharma have completed a commercial pas-de-deux that sees them divide up the Pacific Rim markets for the Solarase, a topical treatment for the pre-cancerous skin condition, actinic or solar keratosis.
UK calls for GM animal advisory body
10 September, 2002 by Melissa TrudingerThe UK's Agriculture and Environment Biotechnology Commission has called for a new advisory body and development of a strategy to deal with issues relating to genetically modified and cloned animals.
Bionomics touts new mouse model, posts loss
09 September, 2002 by Melissa TrudingerA mouse model for inherited epilepsy has been created by Adelaide company Bionomics by 'knocking-in' the human mutation. The model exhibits seizures similar to human epileptic seizures.
Autogen wins US patent for Beacon gene
09 September, 2002 by Melissa TrudingerMelbourne biotech Autogen has been granted a US patent for its Beacon gene, and its use as a therapeutic or diagnostic in conditions like obesity, diabetes and energy imbalance.
Interview: the antisense evangelist
06 September, 2002 by Melissa TrudingerPersistence has paid off for Stanley Crooke and his company Isis Pharmaceuticals.
